ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma [Yahoo! Finance]
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at UBS Group AG from $106.00 to $114.00. They now have a "buy" rating on the stock.
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]